MTOR and cancer: This observation might point to the therapeutic potential of AKT inhibitors to effectively combat not only HPV-dependent cancers with a well-described activation of the PI3K/AKT/mTOR pathway, but also HPV negative ones, and is hypothesis-generating for the future evaluation [39].